In line with independent studies reporting the association of metabolic gene signatures and clinicopathological features in papillary thyroid carcinomas [20–27], our work provides evidence of a strong perturbation of metabolic genes between the two distinct tumour subtypes (i.e., BRAF- and RAS-like PTCs). This evidence concerns the gene BRAF and neoplasm.